With Negma's strong sales and marketing organisation and Wockhardt's global presence, the business will gain further momentum.
Wockhardt has grown its revenues at a CAGR (compounded annual growth rate) of 24% for the last 15 years since Wockhardt's IPO, and has provided an annualised shareholders' return of over 22% per annum during the period.
Apart from being a global pharmaceutical and biotechnology major, Wockhardt is also into the healthcare business with itsown super speciality hospitals in the fields of cardiology, orthopaedics, brain and spine, kidney and other tertiary care. Wockhardt has partnered in scientific and medical areas with Harvard Medical International, an international arm of Harvard Medical School (USA). Wockhardt Group employs about 5500 people belonging to 14 different nationalities.
